Clinical trials: Covid19 Vaccine
COVID-19, Kidney Transplant
COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study
An open label, non-randomized pilot study in kidney transplant recipients who received a completed primary series and bivalent booster of mRNA based COVID-19 vaccine and have ≤2500 U/mL SARS-CoV-2 S antibody concentration using…
- Trial name
- CPAT-SG (NCT05518487)
- Testing
- Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19 Pandemic
A Preliminary Exploratory Study to Evaluate the Safety and Immunogenicity of Omicron Variant Bivalent Vaccine V-01-B5
It is a single center, randomized, open-labeled, exploratory clinical study to evaluate the safety and immunogenicity of Recombinant SARS-CoV-2 Fusion Protein bivalent Vaccine V-01-B5 as a second booster in adults aged 18-59…
- Trial name
- COVID-19 (NCT05585567)
- Testing
- V-01/V-01-B5, V-01-351/V-01-B5, V-01
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
Metabolic Associated Fatty Liver Disease
Clinical Study of SARS-CoV-2 Vaccine in Metabolism-related Fatty Liver Disease
The coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 causes high morbidity and mortality worldwide. SARS-CoV-2 vaccination is currently the most effective means of reducing morbidity, severe illness and mortality risk.
- Trial name
- NCT05738707
- Testing
- Recombinant protein vaccine and adenovirus vector vaccine
- Volunteers
- 100 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Covid19, SARS-CoV2 Infection
COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients
Investigators will evaluate the immunogenicity of a third dose of mRNA-1273 SARS-CoV-2 vaccine among cancer patients receiving the recommended third vaccine dose
- Trial name
- NCT05054218
- Testing
- mRNA-1273
- Where
- United States
- Volunteers
- 336 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
SARS-CoV-2 Infection
Study of a Live rNDV Based Vaccine Against COVID-19
This is a Phase 1, open-label, non-randomized, dose-escalation study using three doses and two schemes of administration of a recombinant vaccine against SARS-CoV-2 based on a viral vector (Newcastle Disease virus) in 90 healthy…
- Trial name
- NCT04871737
- Testing
- Recombinant NDV Vectored Vaccine for SARS-CoV-2
- Where
- Mexico
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Laboratorio Avi-Mex, S.A. de C.V.
Prevention of COVID-19
ZF2001 Booster Immunization Clinical Trials of 12 Months After the Completion of Basic Immunization
The purpose of this study is to evaluate the immunogenicity and safety of the recombinant novel coronavirus vaccine (CHO cells) after the booster immunization.
- Trial name
- NCT05198102
- Testing
- Recombinant novel coronavirus vaccine (CHO cells)
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
mHealth, Social Media
Role of mHealth-based Interventions Including Social Media to Improve Childhood Immunization Coverage During COVID 19 Pandemic in Pakistan: Qualitative Study
In order to improve routine immunization uptake during COVID-19 pandemic, and to understand the perceptions and barriers related to vaccine hesitancy and coverage during COVID 19 and to explore the need for COVID-19 vaccination…
- Conditions
- mHealth, Social Media, Vaccine Hesitancy, Covid19
- Trial name
- NCT05042011
- Where
- Pakistan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Aga Khan University
Vaccine Preventable Disease
COVID-19 Vaccine For Indirect Protection
The primary objective of this study is to test whether vaccinating adults ≥18 years in Hutterite colonies with mRNA-1273 (Moderna COVID-19) vaccine as compared to control (usual care) can prevent RT-PCR confirmed COVID-19 in…
- Trial name
- NCT04818736
- Testing
- COVID-19 Vaccination, Usual care
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- McMaster University
COVID-19
A Trial Evaluate the Immunogenicity and Safety of Recombinant COVID-19 Omicron-Delta Variant Vaccine (CHO Cell)
The study was designed as a randomized, blind and controlled trial. A total of 300 patients aged 18 and above who were immunized with recombinant novel coronavirus protein vaccine (CHO cell) for more than 4 months (60 patients…
- Trial name
- NCT05616754
- Testing
- Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine (CHO cells), Recombinant Novel Coronavirus Protein Vaccine (CHO cells)
- Where
- Uzbekistan
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19 Vaccines
Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes in an Elderly Population
To determine whether a heterologous vaccination regimen in individuals with no known previous history of COVID-19 is non-inferior to that observed with counterpart regimens currently in use in Argentina among a population of…
- Trial name
- NCT04983537
- Testing
- Gam-COVID-Vac / Gam-COVID-Vac
- Where
- 2 sites in Argentina
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Ministerio de Salud de Ciudad Autónoma de Buenos Aires
Covid19, Vaccination
Trusted Messengers: Intervention to Promote COVID-19 Vaccination
The study aims to assess the impact of a multicomponent intervention to support Primary Care Provider (PCP) outreach to promote COVID-19 vaccination among vulnerable patients in and near Worcester, MA via a pragmatic, cluster…
- Trial name
- NCT04981392
- Testing
- Primary care text message outreach to unvaccinated patients and resources to support PCPs
- Where
- United States
- Volunteers
- 21,844 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
COVID-19 Vaccine Adverse Reaction
Safety Study About the mRNA Vaccines Against COVID-19 in Children (PEDIVACOV-HCSC)
Drugs side effects in children need to be evaluated in a different way because of their constant growth and body changes. The use of COVID-19 vaccines (mRNA vaccines) is worldwide spread as a safety measure against the pandemic.
- Trial name
- PEDIVACOV-HCSC (NCT06646744)
- Testing
- mRNA COVID-19 vaccine
- Where
- Spain
- Volunteers
- 2,100 people, healthy volunteers welcome
- Sponsor
- Ana Belen Rivas Paterna
COVID-19
Australian Phase 2b Study to Assess Effect of Dose Interval on Spikogen Covid-19 Vaccine
A study to assess the effect of varying the time interval between doses on the immunogenicity of an adjuvanted recombinant spike protein Covid-19 vaccine (Spikogen/Covax-19)
- Trial name
- NCT05148871
- Testing
- Spikogen/Covax-19
- Where
- Australia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Vaxine Pty Ltd
COVID-19
Study of AZD1222 for the Prevention of COVID-19 in Japan
The COVID-19 pandemic has caused major disruption to healthcare systems with significant socioeconomic impacts. Currently, there are no licensed preventions available against COVID-19 and accelerated vaccine development is…
- Trial name
- NCT04568031
- Testing
- AZD1222, 0.9% (w/v) saline
- Where
- 5 sites in Japan
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Relapsing Multiple Sclerosis (RMS)
A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
This study evaluated if relapsing multiple sclerosis (MS) participants treated with ofatumumab 20 mg subcutaneous (s.c.) administered once monthly could develop an adequate immune response to the COVID-19 mRNA vaccine compared to…
- Trial name
- NCT04878211
- Testing
- Ofatumumab, mRNA COVID-19 vaccine, interferon or glatiramer acetate
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
COVID-19, Vaccination; Infection
Post Covid-19 Vaccination Development or Flare of ARD
Many patients develop autoimmune diseases after covid-19 vaccination, whether related to the vaccination or not, is still under study.
- Conditions
- COVID-19, Vaccination; Infection, Rheumatic Diseases
- Trial name
- PoCov-ARD (NCT05160428)
- Testing
- COVID-19 vaccination
- Where
- Egypt
- Volunteers
- 500 people
- Sponsor
- Cairo University
COVID-19
A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults
This study will evaluate the reactogenicity, safety, and immune response of Flu Seasonal/SARS-CoV-2 mRNA (mRNA Flu/COVID-19) combination vaccine.
- Trial name
- NCT06680375
- Testing
- Flu Seasonal /SARS-CoV-2 mRNA Dose 1, Flu Seasonal /SARS-CoV-2 mRNA Dose 2, Flu Seasonal mRNA
- Where
- 9 sites in United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Vaccine Response, COVID-19 Vaccine
Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine
The goal of this research is to learn more about ZADAXIN® (trade name; thymalfasin generic; Ta1 for short) and determine if Ta1 has any benefit in increasing the immune response to the COVID-19 vaccine.
- Conditions
- Vaccine Response, COVID-19 Vaccine, Immune Response to Covid 19 Vaccination
- Trial name
- NCT06821100
- Testing
- Thymalfasin (Thymosin alpha 1, Ta1)
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- The Methodist Hospital Research Institute
Covid19, Immunosuppression
Humoral and Cellular Immune Response to COVID-19 Vaccines in Immunocompromised and Healthy Individuals
Currently, the efficacy of COVID-19 vaccination in immunodeficient patients is unknown. Here the investigators aim to evaluate the efficacy of COVID-19 vaccines in immunodeficient patients compared to healthy controls.
- Trial name
- CoVVac (NCT04858607)
- Testing
- Blood sample, Saliva sample
- Where
- Austria
- Volunteers
- 373 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Vaccine Adverse Reaction
Genomics and COVID-19 Vaccine Adverse Events
Vaccines routinely used are extremely safe; however, severe adverse events to vaccines do occur. As vaccination against COVID-19 has begun, adverse events to the vaccine, particularly Guillain-Barré syndrome (GBS)…
- Trial name
- NCT05212792
- Testing
- COVID-19 vaccines
- Where
- Canada
- Volunteers
- 6,325 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.